AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of January 30, 2026, AVTX stock price declined to $15.11 with 624,905 million shares trading.

AVTX has a beta of 1.47, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.08 to the broad based SPY ETF.

AVTX has a market cap of $279.73 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $1,130.31 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, VXF, IWC, DFAS, BMED.

AVTX has outperformed the market in the last year with a return of +98.8%, while the SPY ETF gained +16.2%. However, in the most recent history, AVTX shares have underperformed the stock market with its stock returning -16.2% in the last 3 month period and -3.4% for the last 2 week period, while SPY has returned +1.0% and 0.0%, respectively.

AVTX support price is $14.50 and resistance is $16.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.